Clinical trial
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in…
NCT00161746 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161746 |
|---|---|
| Title | Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years |
| Official title | Multicentre Randomized Double-Blind Phase II/III Study on the Safety and Immunogenicity of Three Vaccinations With TICOVAC in Two Dosages in Healthy Children Aged Between Six Months and Three Years |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Encephalitis, Tick-borne |
| Intervention type | Biological |
| Interventions | Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
| Start date | Apr 1, 1998 |
| Completion | Jun 1, 1999 |
| First posted | Sep 13, 2005 |
| Last update posted | May 21, 2015 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: